Cited by 264HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 27 of the 31 references it cites were found in a registry or an index.

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

Open access

Schoeberl, Birgit, Faber, Anthony C., Li, Danan, Liang, Mei-Chih, Crosby, Katherine, Onsum, Matthew, Burenkova, Olga, Pace, Emily, Walton, Zandra, Nie, Lin, Fulgham, Aaron, Song, Youngchul, Nielsen, Ulrik B., Engelman, Jeffrey A., Wong, Kwok-Kin·2010·Cancer Research

DOI 10.1158/0008-5472.can-09-3145PMC PMC2840205

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

ErbB3 is a critical activator of phosphoinositide 3-kinase (PI3K) signaling in epidermal growth factor receptor (EGFR; ErbB1), ErbB2 [human epidermal growth factor receptor 2 (HER2)], and [hepatocyte growth factor receptor (MET)] addicted cancers, and reactivation of ErbB3 is a prominent method for cancers to become resistant to ErbB inhibitors. In this study, we evaluated the in vivo efficacy of a therapeutic anti-ErbB3 antibody, MM-121. We found that MM-121 effectively blocked ligand-dependent activation of ErbB3 induced by either EGFR, HER2, or MET. Assessment of several cancer cell lines revealed that MM-121 reduced basal ErbB3 phosphorylation most effectively in cancers possessing ligand-dependent activation of ErbB3. In those cancers, MM-121 treatment led to decreased ErbB3 phosphorylation and, in some instances, decreased ErbB3 expression. The efficacy of single-agent MM-121 was also examined in xenograft models. A machine learning algorithm found that MM-121 was most effective against xenografts with evidence of ligand-dependent activation of ErbB3. We subsequently investigated whether MM-121 treatment could abrogate resistance to anti-EGFR therapies by preventing reactivation of ErbB3. We observed that an EGFR mutant lung cancer cell line (HCC827), made resistant to gefitinib by exogenous heregulin, was resensitized by MM-121. In addition, we found that a de novo lung cancer mouse model induced by EGFR T790M-L858R rapidly became resistant to cetuximab. Resistance was associated with an increase in heregulin expression and ErbB3 activation. However, concomitant cetuximab treatment with MM-121 blocked reactivation of ErbB3 and resulted in a sustained and durable response. Thus, these results suggest that targeting ErbB3 with MM-121 can be an effective therapeutic strategy for cancers with ligand-dependent activation of ErbB3.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-3145

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Nature of Statistical Learning Theory
Vapnik, V. (2000) · Statistics for Engineering and Information Science · doi:10.1007/978-1-4757-3264-1 · Cited by 46,387
The Nature of Statistical Learning Theory
Vapnik, V. N. (1995) · doi:10.1007/978-1-4757-2440-0 · Cited by 39,138
An overview of statistical learning theory
Vapnik, V. N. (1999) · IEEE Transactions on Neural Networks · doi:10.1109/72.788640 · Cited by 6,420
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Self-citation
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Self-citation
Support Vector Machines and Kernels for Computational Biology
Ben‐Hur, A., Ong, C. S., Sonnenburg, S., Schölkopf, B., & Rätsch, G. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000173 · Cited by 726

Show all 31 references

Research works printed but not linked: 1

Burnham, 2002, Model Selection and Multimodel Interference

Sorted by citations

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Self-citation
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3309 · Cited by 1,031
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 878
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Self-citation
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Huang, L., & Fu, L. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.001 · Cited by 596
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 386
Spatial regulation of receptor tyrosine kinases in development and cancer
Casaletto, J. B., & McClatchey, A. I. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3277 · Cited by 374
A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
Schaefer, G., Haber, L., Crocker, L., Shia, S., Shao, L., Dowbenko, D. J., Tótpál, K., Wong, A., Lee, C. V., Stawicki, S. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Pradeep, S., Kim, S. W., Wu, S. Y., Nishimura, M., Chaluvally–Raghavan, P., Miyake, T. M., Pecot, C. V., Kim, S.-J., Choi, H. J., Bischoff, F. Z., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.002 · Cited by 306
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 288
Software for systems biology: from tools to integrated platforms
Ghosh, S., Matsuoka, Y., Asai, Y., Hsin, K., & Kitano, H. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3096 · Cited by 260
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Abel, E. V., Basile, K. J., Kugel, C. H., Witkiewicz, A. K., Le, K., Amaravadi, R. K., Karakousis, G. C., Xu, X., Xu, W., Schuchter, L. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65780 · Cited by 249
Recent therapeutic trends and promising targets in triple negative breast cancer
Hwang, S., Park, S., & Kwon, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.006 · Cited by 239
HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
Ocaña, A., Vera-Badillo, F., Šeruga, B., Templeton, A. J., Pandiella, A., & Amir, E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs501 · Cited by 226
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Maennling, A. E., Tur, M. K., Niebert, M., Klockenbring, T., Zeppernick, F. A., Gattenlöhner, S., Meinhold-Heerlein, I. M., & Hussain, A. F. (2019) · Cancers · doi:10.3390/cancers11121826 · Cited by 226
Pharmacological targeting of the pseudokinase Her3
Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1658 · Cited by 205
Molecular Pathways: HER3 Targeted Therapy
Gala, K. P., & Chandarlapaty, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1549 · Cited by 200
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
Garrett, J. T., & Arteaga, C. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15045 · Cited by 188
Targeting of erbB3 receptor to overcome resistance in cancer treatment
Ma, J., Lyu, H., Huang, J., & Liu, B. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-105 · Cited by 176
Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
Tinoco, G., Warsch, S., Glück, S., Avancha, K. K. V. R., & Montero, A. J. (2013) · Journal of Cancer · doi:10.7150/jca.4925 · Cited by 179
HER3 signaling and targeted therapy in cancer
Mishra, R., Patel, H. M., Alanazi, S., Yuan, L., & Garrett, J. T. (2018) · Oncology Reviews · doi:10.4081/oncol.2018.355 · Cited by 175
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 179
Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling
Boeck, A. D., Pauwels, P., Hensen, K., Rummens, J., Westbroek, W., Hendrix, A., Maynard, D., Denys, H. G., Lambein, K., Braems, G., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301393 · Cited by 170
Prospects for pharmacological targeting of pseudokinases
Kung, J. E., & Jura, N. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0018-3 · Cited by 144
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
Wang, S., Huang, J., Lyu, H., Lee, C., Tan, M. J., Wang, J., & Liu, B. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.79 · Cited by 128
Understanding the biology of HER3 receptor as a therapeutic target in human cancer
Lyu, H., Han, A., Polsdofer, E., Liu, S., & Liu, B. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.010 · Cited by 125
How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Politi, K. A., & Pao, W. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 126
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
Geuijen, C. A. W., Nardis, C. D., Maussang, D., Rovers, E., Gallenne, T., Hendriks, L. J. A., Visser, T., Nijhuis, R., Logtenberg, T., de Kruif, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.003 · Cited by 108
Regulation of ERBB3/HER3 signaling in cancer
Mujoo, K., Choi, B.-K., Huang, Z., Zhang, N., & An, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2655 · Cited by 107
Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance
Zhai, Z., Yu, X., Yang, B. J., Zhang, Y., Zhang, L., Li, X., & Sun, H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.033 · Cited by 110
MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V. M., Xu, L., Kohli, N., Rennard, R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0255 · Cited by 106
Self-citation
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
Mirschberger, C., Schiller, C., Schräml, M., Dimoudis, N., Friess, T., Gerdes, C. A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0099 · Cited by 103
Chemotherapy-Resistant Metastatic Breast Cancer
Marquette, C., & Nabell, L. M. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0184-6 · Cited by 103
New perspectives on targeted therapy in ovarian cancer
Coward, J. I. G., Middleton, K., & Murphy, F. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s52379 · Cited by 103
HER3 in cancer: from the bench to the bedside
Gandullo‐Sánchez, L., Ocaña, A., & Pandiella, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02515-x · Cited by 101
Breast cancer: Current and future endocrine therapies
Palmieri, C., Patten, D. K., Januszewski, A. P., Zucchini, G., & Howell, S. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.001 · Cited by 102
Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
Fernandez‐Cuesta, L., & Thomas, R. K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0854 · Cited by 95
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
Yonesaka, K., Hirotani, K., Kawakami, H., Takeda, M., Kaneda, H., Sakai, K., Okamoto, I., Nishio, K., Janne, P. A., & Nakagawa, K. (2015) · Oncogene · doi:10.1038/onc.2015.142 · Cited by 90
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
Garrett, J. T., Sutton, C. R., Kurupi, R., Bialucha, C. U., Ettenberg, S. A., Collins, S. D., Sheng, Q., Wallweber, J., Eli, L. D., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1191 · Cited by 87
The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC ‐γ 1 signalling in breast cancer cell migration and dissemination
Balz, L. M., Bartkowiak, K., Andreas, A., Pantel, K., Niggemann, B., Zänker, K. S., Brandt, B., & Dittmar, T. (2012) · The Journal of Pathology · doi:10.1002/path.3991 · Cited by 87
Novel therapeutic targets for pancreatic cancer
Tang, S.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i31.10825 · Cited by 85
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Liu, J. F., Ray-Coquard, I. L., Selle, F., Poveda, A. M., Cibula, D., Hirte, H. W., Hilpert, F., Raspagliesi, F., Gladieff, L., Harter, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1891 · Cited by 84
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
Aurisicchio, L., Marra, E., Roscilli, G., Mancini, R., & Ciliberto, G. (2012) · Oncotarget · doi:10.18632/oncotarget.550 · Cited by 83
Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3
Ling, B., Wang, G., Long, G., Qiu, J., & Hu, Z.-L. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1194-2 · Cited by 83
Antibodies directed against receptor tyrosine kinases
Fauvel, B., & Yasri, A. (2014) · mAbs · doi:10.4161/mabs.29089 · Cited by 81
Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Jathal, M. K., Chen, L., Mudryj, M. M., & Ghosh, P. (2011) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152211795495643 · Cited by 80
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines
Barnabas, N., & Cohen, D. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/872743 · Cited by 79
ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis
Cook, R. S., Garrett, J. T., Sanchez, V. M., Stanford, J. C., Young, C. D., Chakrabarty, A., Rinehart, C., Zhang, Y., Wu, Y., Greenberger, L. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3775 · Cited by 78
HER3/ErbB3, an emerging cancer therapeutic target
Zhang, N., Chang, Y., Rios, A. A., & An, Z. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv103 · Cited by 75
Efficient [18F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors
Pieve, C. D., Allott, L., Martins, C. D., Vardon, A., Ciobota, D. M., Krämer-Marek, G., & Smith, G. S. T. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00259 · Cited by 75
Current Approaches in NSCLC Targeting K-RAS and EGFR
Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Schoeberl, B., Kudla, A. J., Masson, K., Kalra, A. V., Curley, M., Finn, G. J., Pace, E. A., Harms, B. D., Kim, J., Kearns, J. D., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/npjsba.2016.34 · Cited by 73
Self-citation
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
Watanabe, S., Yonesaka, K., Tanizaki, J., Nonagase, Y., Takegawa, N., Haratani, K., Kawakami, H., Hayashi, H., Takeda, M., Tsurutani, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1995 · Cited by 72
Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
Liu, X., Liu, S., Lyu, H., Riker, A. I., Zhang, Y., & Liu, B. (2019) · Biological Procedures Online · doi:10.1186/s12575-019-0093-1 · Cited by 72
A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
Mota, J. M., Collier, K. A., Costa, R. L. B., Taxter, T., Kalyan, A., Leite, C. A., Chae, Y. K., Giles, F. J., & Carneiro, B. A. (2017) · Oncotarget · doi:10.18632/oncotarget.18467 · Cited by 70
The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling
Huang, Z., Choi, B.-K., Mujoo, K., Fan, X., Fa, M.-J., Mukherjee, S., Owiti, N. A., Zhang, N., & An, Z. (2014) · Oncogene · doi:10.1038/onc.2014.56 · Cited by 69
Development of small molecules targeting the pseudokinase Her3
Lim, S. M., Xie, T., Westover, K. D., Ficarro, S. B., Tae, H. S., Gurbani, D., Sim, T., Marto, J. A., Janne, P. A., Crews, C. M., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.103 · Cited by 68
HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Wang, D., Qian, G., Zhang, H., Magliocca, K. R., Nannapaneni, S., Amin, A. R. M. R., Rossi, M., Patel, M. R., El‐Deiry, M. W., Wadsworth, J. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0558 · Cited by 68
ERBB3 is required for metastasis formation of melanoma cells
Tiwary, S., Preziosi, M., Rothberg, P. G., Zeitouni, N. C., Corson, N., & Xu, L. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.23 · Cited by 65
New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
Abramson, V. G., & Arteaga, C. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1947 · Cited by 66
Overexpression of HER2/HER3 and clinical feature of ovarian cancer
Chung, Y. W., Kim, S., Hong, J. H., Lee, J. K., Lee, N. W., Lee, Y. S., & Song, J. Y. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e75 · Cited by 64
HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines
Okita, R., Mougiakakos, D., Ando, T., Mao, Y., Sarhan, D., Wennerberg, E., Seliger, B., Lundqvist, A., Mimura, K., & Kiessling, R. W. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102237 · Cited by 64
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
Huang, J., Wang, S., Lyu, H., Cai, B., Yang, X., Wang, J., & Liu, B. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-134 · Cited by 64
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 64
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
Yonesaka, K., Kudo, K., Nishida, S., Takahama, T., Iwasa, T., Yoshida, T., Tanaka, K., Takeda, M., Kaneda, H., Okamoto, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5286 · Cited by 64
HER3, serious partner in crime
Kol, A., van Scheltinga, A. G. T. T., Timmer‐Bosscha, H., Lamberts, L. E., Bensch, F., de Vries, E. G. E., & Schroder, C. P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.005 · Cited by 61
Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
Chen, L., Mooso, B. A., Jathal, M. K., Madhav, A., Johnson, S. D., Spyk, E. N. V., Mikhailova, M., Ripoll, A. Z., Xue, L., Vinall, R. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1548 · Cited by 61
Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Jiang, N., Wang, D., Hu, Z., Shin, H. J. C., Qian, G., Rahman, M. A., Zhang, H., Amin, A. R. M. R., Nannapaneni, S., Wang, X., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1093 · Cited by 61
Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Meetze, K. A., Vincent, S., Tyler, S. M., Mazsa, E. K., Delpero, A. R., Bottega, S., McIntosh, D., Nicoletti, R., Winston, W. M., Weiler, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2407 · Cited by 56
High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer
Davies, S., Holmes, A. M., Lomo, L. C., Steinkamp, M. P., Kang, H., Muller, C. Y., & Wilson, B. S. (2014) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000081 · Cited by 56
ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Zhang, L., Castanaro, C., Luan, B., Yang, K., Fan, L., Fairhurst, J. L., Rafique, A., Potocky, T. B., Shan, J., Delfino, F. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1033 · Cited by 56
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
Gaborit, N., Lindzen, M., & Yarden, Y. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1102809 · Cited by 56
Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab
Shu, M., Gao, F., Yu, C., Zeng, M., He, G., Wu, Y., Su, Y., Hu, N., Zhou, Z., Yang, Z., et al. (2020) · Nanotechnology · doi:10.1088/1361-6528/ab8a8a · Cited by 56
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
Rios‐Doria, J., Sabol, D., Chesebrough, J. W., Stewart, D., XU, L. L., Tammali, R., Cheng, L., Du, Q., Schifferli, K. P., Rothstein, R., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1040 · Cited by 55
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
Wang, S., Huang, J., Lyu, H., Cai, B., Yang, X., Li, F., Tan, M. J., Edgerton, S. M., Thor, A. D., Lee, C., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3563 · Cited by 53
Advances in Targeting HER3 as an Anticancer Therapy
Jiang, N., Saba, N. F., & Chen, Z. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817304 · Cited by 53
Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Brand, T. M., Hartmann, S., Bhola, N. E., Peyser, N. D., Li, H., Zeng, Y., Wechsler, E. I., Ranall, M. V., Bandyopadhyay, S., Duvvuri, U., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2203 · Cited by 53
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
Majumder, A., Sandhu, M., Banerji, D., Steri, V., Olshen, A. B., & Moasser, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-88683-w · Cited by 52
Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
Jacob, W., James, I., Hasmann, M., & Weisser, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.011 · Cited by 52
Peptide Vaccines and Peptidomimetics Targeting HER and VEGF Proteins May Offer a Potentially New Paradigm in Cancer Immunotherapy
Kaumaya, P. T. P., & Foy, K. C. (2012) · Future Oncology · doi:10.2217/fon.12.95 · Cited by 51
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Maron, R., Schechter, B., Mancini, M., Mahlknecht, G., Yarden, Y., & Sela, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313857110 · Cited by 50
Molecular mechanism matters: Benefits of mechanistic computational models for drug development
Clegg, L. E., & Gabhann, F. M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.002 · Cited by 50
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
Mendell, J., Freeman, D. J., Feng, W., Hettmann, T., Schneider, M. B., Blum, S., Ruhe, J. E., Bange, J., Nakamaru, K., Chen, S., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.005 · Cited by 49
The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy
Austreid, E., Lønning, P. E., & Eikesdal, H. P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.885952 · Cited by 49
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
Malm, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2016) · mAbs · doi:10.1080/19420862.2016.1212147 · Cited by 52
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Odintsov, I., Lui, A. J. W., Sisso, W. J., Gladstone, E., Liu, Z., Delasos, L., Kurth, R. I., Sisso, E. M., Vojnic, M., Khodos, I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3605 · Cited by 49
Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma
Hsieh, S., He, J., Hsu, C., Chen, W.-J., Bera, R., Lin, K.-Y., Shih, T., Yu, M.-C., Lin, Y., Chang, C., et al. (2010) · Hepatology · doi:10.1002/hep.24083 · Cited by 47
Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration
Lee, S., Greenlee, E. B., Amick, J., Ligon, G. F., Lillquist, J. S., Natoli, E. J., Hadari, Y. R., Alvarado, D., & Schlessinger, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518361112 · Cited by 46
Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma
Liles, J. S., Arnoletti, J. P., Kossenkov, A. V., Mikhaylina, A., Frost, A. R., Kulesza, P., Heslin, M. J., & Frolov, A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.263 · Cited by 45
Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice
Zou, Z., Bellenger, S., Massey, K. A., Nicolaou, A., Geissler, A., Bidu, C., Bonnotte, B., Pierre, A.-S., Minville-Walz, M., Rialland, M., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m042754 · Cited by 45
Targeting protein quality control pathways in breast cancer
Sannino, S., & Brodsky, J. L. (2017) · BMC Biology · doi:10.1186/s12915-017-0449-4 · Cited by 43
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
Kamath, A. V., Lu, D., Gupta, P., Jin, D., Xiang, H., Wong, A., Leddy, C., Crocker, L., Schaefer, G., Sliwkowski, M. X., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1806-6 · Cited by 41
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.01.010 · Cited by 41
A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3receptortyrosinekinasesignaling network
Telesco, S., Shih, A., Jia, F., & Radhakrishnan, R. (2011) · Molecular BioSystems · doi:10.1039/c0mb00345j · Cited by 40
Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network
Lebedeva, G., Sorokin, A., Faratian, D., Mullen, P., Goltsov, A., Langdon, S. P., Harrison, D. J., & Goryanin, I. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.10.026 · Cited by 40
Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation
Lazrek, Y., Dubreuil, O., Garambois, V., Gaborit, N., Larbouret, C., Clorennec, C. L., Thomas, G., Leconet, W., Jarlier, M., Pugnière, M., et al. (2013) · Neoplasia · doi:10.1593/neo.121960 · Cited by 40
Secreted ERBB3 Isoforms Are Serum Markers for Early Hepatoma in Patients with Chronic Hepatitis and Cirrhosis
Hsieh, S., He, J., Yu, M.-C., Lee, W., Chen, T., Lo, S., Bera, R., Sung, C., & Chiu, C. (2011) · Journal of Proteome Research · doi:10.1021/pr200519q · Cited by 39
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Meulendijks, D., Jacob, W., Voest, E. E., Mau‐Sørensen, M., Martinez‐García, M., Taus, Á., Fleitas, T., Cervantes, A. M. R., Lolkema, M. P., Langenberg, M. H. G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0812 · Cited by 39
The role of ErbB3 binding protein 1 in cancer: Friend or foe?
Nguyen, D. Q., Hoang, D. H., Vo, T. T. N., Huynh, V., Ghoda, L. Y., Marcucci, G., & Nguyen, L. X. T. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26951 · Cited by 39
Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models
Wu, Y., Zhang, Y., Wang, M., Li, Q., Qu, Z., Shi, V., Kraft, P., Kim, S. H., Gao, Y. J., Pak, J., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0838 · Cited by 39

Authors: Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., Fulgham, A., Song, Y., Nielsen, U. B., Engelman, J. A., & Wong, K.-K.
Affiliations: Harvard University (US)
Corresponding author: Engelman, Jeffrey A.
Wong, Kwok-Kin
ORCID: Schoeberl, Birgit
Faber, Anthony C.
Liang, Mei-Chih
Burenkova, Olga
Pace, Emily
Walton, Zandra
Song, Youngchul
Nielsen, Ulrik B.
Engelman, Jeffrey A.
Wong, Kwok-Kin
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-03-14
Volume: 70
Issue: 6
Pages: 2485-2494
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-09-3145
PMC: PMC2840205
OpenAlex: W2120213327
Cited by: 264
References: 31
Citations by year: 2026: 2 · 2024: 5 · 2023: 8 · 2022: 11 · 2021: 10 · 2020: 8 · 2019: 10 · 2018: 19 · 2017: 16 · 2016: 26 · 2015: 31 · 2014: 29 · 2013: 29 · 2012: 29
FWCI: 14.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Aging (R01AG2400401, K08AG024004, R01AG027757)
National Cancer Institute (P50CA127003, CA120060, R01CA122794, R01CA140594, P50CA090578, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: HER3, ligand-dependent receptor activation, EGFR, HER2, MET, PI3K signaling, gefitinib resistance, cetuximab resistance, neuregulin-1, EGFR inhibitor resistance, xenograft models
MeSH terms: Cetuximab, Gefitinib, Animals, Antibodies, Monoclonal, Cricetulus, Cricetinae, Humans, Ligands, Neoplasms, Quinazolines, CHO Cells, Neuregulin-1, Receptor, ErbB-3, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks